160 related articles for article (PubMed ID: 37438734)
1. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Mohebi R; Liu Y; Hansen MK; Yavin Y; Sattar N; Pollock CA; Butler J; Jardine M; Masson S; Heerspink HJL; Januzzi JL
Cardiovasc Diabetol; 2023 Jul; 22(1):176. PubMed ID: 37438734
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK
Circulation; 2023 Aug; 148(8):651-660. PubMed ID: 37603600
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Januzzi JL; Liu Y; Sattar N; Yavin Y; Pollock CA; Butler J; Jardine M; Heerspink HJL; Masson S; Breyer M; Hansen MK
Am Heart J; 2024 May; 271():38-47. PubMed ID: 38401646
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
5. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M;
Am J Kidney Dis; 2023 Jul; 82(1):84-96.e1. PubMed ID: 36889425
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
[TBL] [Abstract][Full Text] [Related]
7. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
8. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
9. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
[TBL] [Abstract][Full Text] [Related]
10. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
11. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
12. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
13. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
[TBL] [Abstract][Full Text] [Related]
16. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
19. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
20. The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial.
Zandbergen AA; Lamberts SW; Baggen MG; Janssen JA; Boersma E; Bootsma AH
Clin Endocrinol (Oxf); 2006 Feb; 64(2):203-8. PubMed ID: 16430721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
